SLC5A5 and plasma cell myeloma: Despite that, prolonged survival was established in pancreatic cancer patients treated with VEE-CEA [150], stable disease in ovarian cancer patients immunized with MV-CEA [149] and complete remission in one patient with refractory multiple myeloma after treatment with MV-NIS [148].